M Ameratunga1, G McArthur2,3,4, H Gan1, L Cher1. 1. Department of Medical Oncology, Austin Health, Heidelberg, Vic, Australia. 2. Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia. 3. University of Melbourne, Parkville, Vic, Australia. 4. St. Vincent's Hospital, University of Melbourne, Fitzroy, Vic, Australia.
Abstract
WHAT IS KNOWN AND OBJECTIVE: Neurofibromatosis is associated with overactivation of the RAS-MAPK pathway. MEK inhibitors have been shown to be an effective treatment modality in other malignancies. CASE SUMMARY: We present a 24-year-old male with treatment-refractory neurofibromatosis-associated glioblastoma, who experienced clinical and radiological benefit from the MEK inhibitor, trametinib. WHAT IS NEW AND CONCLUSION: This case highlights the therapeutic success of a MEK inhibitor in neurofibromatosis-associated glioblastoma. As a corollary, this should prompt evaluation of MEK inhibitors in tumours associated with neurofibromatosis. It remains to be elucidated if tumours with somatic NF1 mutations may also benefit from therapy targeting the RAS-MAPK pathway.
WHAT IS KNOWN AND OBJECTIVE:Neurofibromatosis is associated with overactivation of the RAS-MAPK pathway. MEK inhibitors have been shown to be an effective treatment modality in other malignancies. CASE SUMMARY: We present a 24-year-old male with treatment-refractory neurofibromatosis-associated glioblastoma, who experienced clinical and radiological benefit from the MEK inhibitor, trametinib. WHAT IS NEW AND CONCLUSION: This case highlights the therapeutic success of a MEK inhibitor in neurofibromatosis-associated glioblastoma. As a corollary, this should prompt evaluation of MEK inhibitors in tumours associated with neurofibromatosis. It remains to be elucidated if tumours with somatic NF1 mutations may also benefit from therapy targeting the RAS-MAPK pathway.
Authors: Amy K Bruzek; Andrew H Zureick; Paul E McKeever; Hugh J L Garton; Patricia L Robertson; Rajen Mody; Carl J Koschmann Journal: Pediatr Blood Cancer Date: 2016-11-10 Impact factor: 3.167
Authors: Elisa Izquierdo; Diana M Carvalho; Alan Mackay; Sara Temelso; Jessica K R Boult; Giulia Pericoli; Elisabet Fernandez; Molina Das; Valeria Molinari; Yura Grabovska; Rebecca F Rogers; Maria Antonietta Ajmone-Cat; Paula Z Proszek; Mark Stubbs; Sarita Depani; Patricia O'Hare; Lu Yu; Georgia Roumelioti; Jyoti S Choudhary; Matthew Clarke; Amy R Fairchild; Thomas S Jacques; Richard G Grundy; Lisa Howell; Susan Picton; Jenny Adamski; Shaun Wilson; Juliet C Gray; Bassel Zebian; Lynley V Marshall; Fernando Carceller; Jacques Grill; Maria Vinci; Simon P Robinson; Michael Hubank; Darren Hargrave; Chris Jones Journal: Cancer Discov Date: 2022-03-01 Impact factor: 39.397
Authors: Ming Yuan; Charles G Eberhart; Christine A Pratilas; Jaishri O Blakeley; Christine Davis; Marija Stojanova; Karlyne Reilly; Alan K Meeker; Christopher M Heaphy; Fausto J Rodriguez Journal: Cancers (Basel) Date: 2022-06-19 Impact factor: 6.575
Authors: Bernard L Marini; Lydia L Benitez; Andrew H Zureick; Ralph Salloum; Angela C Gauthier; Julia Brown; Yi-Mi Wu; Dan R Robinson; Chandan Kumar; Robert Lonigro; Pankaj Vats; Xuhong Cao; Katayoon Kasaian; Bailey Anderson; Brendan Mullan; Benjamin Chandler; Joseph R Linzey; Sandra I Camelo-Piragua; Sriram Venneti; Paul E McKeever; Kathryn A McFadden; Andrew P Lieberman; Noah Brown; Lina Shao; Marcia A S Leonard; Larry Junck; Erin McKean; Cormac O Maher; Hugh J L Garton; Karin M Muraszko; Shawn Hervey-Jumper; Jean M Mulcahy-Levy; Adam Green; Lindsey M Hoffman; Katie Dorris; Nicholas A Vitanza; Joanne Wang; Jonathan Schwartz; Rishi Lulla; Natasha Pillay Smiley; Miriam Bornhorst; Daphne A Haas-Kogan; Patricia L Robertson; Arul M Chinnaiyan; Rajen Mody; Carl Koschmann Journal: Transl Res Date: 2017-08-10 Impact factor: 7.012
Authors: Sara A Byron; Nhan L Tran; Rebecca F Halperin; Joanna J Phillips; John G Kuhn; John F de Groot; Howard Colman; Keith L Ligon; Patrick Y Wen; Timothy F Cloughesy; Ingo K Mellinghoff; Nicholas A Butowski; Jennie W Taylor; Jennifer L Clarke; Susan M Chang; Mitchel S Berger; Annette M Molinaro; Gerald M Maggiora; Sen Peng; Sara Nasser; Winnie S Liang; Jeffrey M Trent; Michael E Berens; John D Carpten; David W Craig; Michael D Prados Journal: Clin Cancer Res Date: 2017-10-26 Impact factor: 12.531